達仁堂(600329.SH):擬以不超4.5億元收購京萬紅藥業47.9826%股權
格隆匯9月19日丨達仁堂(600329.SH)公佈,公司2022年第七次董事會決議,審議通過了公司收購控股子公司天津達仁堂京萬紅藥業有限公司少數股東股權暨簽署《股權收購意向書》的議案。
董事會同意公司行使優先購買權,以自有資金收購天津津蘭集團公司所持有的天津達仁堂京萬紅藥業有限公司(“京萬紅藥業”)47.9826%股權,收購價格不超過人民幣4.5億元,並與天津津蘭集團公司簽署《股權收購意向書》。此次交易成交金額上限,佔公司最近一期經審計歸母淨資產的7.07%。此次交易不構成關聯交易,且不構成重大資產重組。收購完成後,公司將持有京萬紅藥業100%股權。
此次收購符合公司戰略發展規劃,交易完成後京萬紅藥業將成為公司的全資子公司,有利於提高公司對子公司的決策效率,降低管理成本與風險;京萬紅藥業的主要產品“京萬紅軟膏”與“痺祺膠囊”分別是公司“三核九翼”戰略的主打產品,此次收購有利於公司聚焦“三核”之一的“皮膚創面修復”與“九翼”之一的“風濕骨病”領域,進一步深耕細作;有利於提高歸屬於母公司股東的淨利潤,提升公司的整體經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.